Tirzepatide
Late clinicalDual GLP-1/GIP — appetite control, metabolic support
15% off your first order15% off your first order — applied at checkout
Body Composition
Aggressive fat loss with metabolic + endurance support.
Tirzepatide and MOTS-c are examined together because they are studied at different levels of metabolic regulation. Tirzepatide is a dual GIP and GLP-1 receptor agonist evaluated in multiple randomized phase 3 trials for weight reduction, appetite, energy intake, and fat mass. MOTS-c is a mitochondrial-encoded peptide studied as a signal between the mitochondria and the nucleus, with research focused on AMPK-associated pathways governing cellular energy management and metabolic homeostasis. The pairing therefore links incretin-driven appetite and glucose signaling with cellular energy regulation. The evidence bases differ considerably: MOTS-c research remains largely preclinical, and human safety data for MOTS-c are limited.
Dual GLP-1/GIP — appetite control, metabolic support
Mitochondrial activation, metabolic flexibility
All components in stock
$238.00components, bought separately
The builder puts together a stack for this goal, with supplies, and every order ships with a protocol guide for the compounds in it.
Products described on this site are provided for research purposes. Nothing here is a medical claim, and no product is intended to diagnose, treat, cure, or prevent any disease. See our methodology for how this content is sourced and reviewed.